复方牛胎肝提取物治疗乙型肝炎肝硬化疗效观察

doi:10.3969/j.issn.1672-5069.2015.02.011

摘要/Abstract

摘要： 目的探讨复方牛胎肝提取物治疗乙型肝炎肝硬化患者的疗效。方法将120例乙型肝炎肝硬化患者随机分为治疗组80例和对照组40例。给予治疗组复方牛胎肝联合基础护肝治疗,对照组仅予以基础护肝治疗,疗程3个月,对比两组患者治疗前后肝功能、肝脏硬度值（LSM）,以及B超检测门静脉内径、脾脏厚度、脾静脉宽度的变化。结果在3个月治疗结束时,治疗组患者血清TBIL为（33.0±2.07） μmol/L、ALT为（36.40±5.86） U/L、LSM为（10.78±1.15） Kpa,均较对照组显著下降[分别为（48.62±4.24） μmol/L、（52.60±7.3） U/L、（15.26±2.17）Kpa,P<0.05];治疗组血清ALB水平为（35.0±1.58） g/L,较对照组明显升高[（31±1.58）g/L,P<0.05];治疗组门静脉内径为（1.26±0.08） cm, 脾脏厚度为（3.97±0.04）cm,脾静脉宽度为（0.87±0.02）cm,均较对照组显著降低[分别为（1.36±0.05） cm、（4.20±0.10） cm、（0.92±0.02） cm,P<0.05]。结论复方牛胎肝提取物可显著改善乙型肝炎肝硬化患者的肝功能,减轻肝纤维化程度。

关键词: 肝硬化, 乙型肝炎, 复方牛胎肝提取物, 疗效

Abstract: Objective To investigate the effect of compound embryonic bovine liver extract in patients with hepatitis B related liver cirrhosis. Methods One hundred and twenty patients with hepatitis B induced liver cirrhosis were randomly divided into two groups,with 80 in treatment group receiving compound embryonic bovine liver extract tablets at the base of basic liver-protecting treatment and 40 in control group receiving the basic liver-protecting treatment only for 3 months. Liver function tests,liver stiffness measurement（LSM） by Fibrotouch,and portal vein diameters,spleen thickness and splenic vein width before and after treatment were compared in both groups. Results At the end of 3-month treatment,serum TBIL,ALT,and LSM values in patients in treatment group were（33.0±2.07） μmol/L,（36.40±5.86） U/L,（10.78±1.15） Kpa, respectively, significantly decreased as compared with those in the controls[（48.62±4.24） μmol/L,（52.60±7.3） U/L,（15.26±2.17） Kpa,respectively, P<0.05 for all];serum ALB levels in patients in treatment group increased significantly compared with that in controls[（35.0±1.58） g/L vs. （31±1.58） g/L,P<0.05];portal vein diameters,spleen thickness and splenic vein widths remarkably decreased compared with those in patients in the control group [（1.26±0.08） cm vs. （1.36±0.05） cm,（3.97±0.04） cm vs. （4.20±0.10） cm,（0.87±0.02） cm vs. （0.92±0.02） cm,P<0.05 for all]. Conclusions Compound embryonic bovine liver extract can significantly improve the liver function and inhibit liver fibrosis in patients with hepatitis B induced liver cirrhosis.

Key words: Liver cirrhosis, Compound embryonic bovine liver extract, Hepatitis B, Efficacy

卢敏, 毛华, 黄纯炽, 唐银丽, 张能友, 席建东. 复方牛胎肝提取物治疗乙型肝炎肝硬化疗效观察[J]. 实用肝脏病杂志, 2015, 18(3): 262-265.

Lu Min, Mao Hua, Huang Chunchi, et al.. Efficacy of compound embryonic bovine liver extract in patients with hepatitis B related liver cirrhosis[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2015, 18(3): 262-265.

参考文献

[1] 郑翀,黄宝如,王鹏,等. 复方牛胎肝提取物联合阿德福韦酯治疗慢性乙型肝炎疗效观察. 实用肝脏病杂志,2012,15（5）:404-406.
[2] 何吕富. 拉米夫定联合安珐特治疗慢性乙型病毒性肝炎肝纤维化的临床研究. 现代医药卫生,2008,24（10）:1447-1448.
[3] 中华医学会肝病学分会和感染病学分会. 慢性乙型肝炎防治指南（2010年版）.实用肝脏病杂志,2011,14（2）:81-89.
[4] Chan HLY,Sung JJY. Hepatocellular carcinoma and hepatitis B virus. Sem Liver Dis,2006,26:153-161.
[5] 黄红丽,胡志文,聂玉强,等. 复方牛胎肝提取物联合恩替卡韦治疗慢性乙型肝炎疗效分析.实用肝脏病杂志,2014,17（1）：41-44.
[6] 胡希亚,王鲁文,马金春,等.复方牛胎肝提取物治疗慢性乙型肝炎患者对肝纤维化指标的影响.实用肝脏病杂志,2010,2（13）：37-38.
[7] 李烨,黄腊平,彭红兵,等. 非酒精性脂肪肝的中西医结合治疗.中国临床实用医学,2010,4（1）:199-201.
[8] Marcellin P,Ziol M,Bedossa P,et al. Non-invasive assessment of liver fibrosis by stiffness measurement in patients with chronic hepatitis B. Liver Int,2009,29（2）:242-247.
[9] 刘伟,丁艾昆,李程,等. 慢性乙型肝炎疾病进展中瞬时弹性波检测的意义及其影响因素. 山东大学学报,2014,52（1）:85-88.
[10] 余桂芳,朱科伦,曾文铤,等. 慢性乙型肝炎肝纤维化程度与脾静脉直径、脾脏大小相关关系探讨.安徽医学,2007,28（1）:20-21.
[11] 谢冬英,谢仕斌,李勇忠,等. 肝纤维化与门静脉、脾静脉直径、脾脏大小及血细胞计数的关系.中华消化杂志,2000,20（5）:308-310.
[12] O’Donhue J,Ng,C,Catnach S,et al. Diagnostic value of Doppler assessment of the hepatic and portal vessels and ultrasound of the spleen in liver disease. Eur J Gastroenterol Hepatol,2004,16（2）:147-155.
[13] 丁红兵,李奕鑫,赖江琼,等. 慢性乙型肝炎患者肝组织病理学改变与门静脉内径的相关性分析.实用肝脏病杂志,2010,13（5）:369-370.
[14] 尉秀清,文卓夫,郑丰平,等. 脾静脉管径及脾脏厚度与肝组织纤维化程度关系的研究.中国热带医学,2006,6（3）：449-450.
[15] 孙涛,毛华,王倩. 复方牛胎肝提取物治疗慢性乙型肝炎疗效观察. 实用肝脏病杂志,2014,17（1）：45-47.
[16] Zhang X,Wang SZ, Zheng JF,et al. Clinical efficacy of tolvaptan for treatment of refractory ascites in liver cirrhosis patients. World J Gastroenterol,2014,20（32）:11400-11405.
[17] Woo HY,Choi JY,Yoon SK,et al. Rescue therapy with adefovir in decompensated liver cirrhosis patients with lamivudine-resistant hepatitis B virus. Clin Mol Hepatol,2014,20（2） :168-176.
[18] Chung GE,Lee JH,Kim YJ. Does antiviral therapy reduce complications of cirrhosis World J Gastroenterol,2014,20（23）: 7306-7311.
[19] Yang X,Li J,Zhou L,et al. Comparison of telbivudine efficacy in treatment-naive patients with hepatitis B virus-related compensated and decompensated cirrhosis in 96 weeks. Eur J Gastroenterol Hepatol,2014,26（4）:396-403.
[20] Lo GH. Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with cirrhosis:facts or fiction?Hepatology,2014,60（5）:1797.
[21] Terai S,Takami T,Yamamoto N,et al. Status and prospects of liver cirrhosis treatment by using bone marrow-derived cells and mesenchymal cells. Tissue Eng Part B Rev,2014,20（3）: 206-210.
[22] Li CZ,Cheng LF,Li QS,et al. Antiviral therapy delays esophageal variceal bleeding in hepatitis B virus-related cirrhosis. World J Gastroenterol,2013,19（40）:6849-6856.
[23] Lian JS,Zeng LY,Chen JY,et al. De novo combined lamivudine and adefovir dipivoxil therapy vs entecavir monotherapy for hepatitis B virus-related decompensated cirrhosis. World J Gastroenterol,2013,19（37）:6278-6283.
[24] Roche B,Samuel D. Treatment of patients with HBV-related decompensated cirrhosis and liver transplanted patients. Clin Liver Dis,2013,17（3）:451-473.
[25] Lyu GC,Yao JM,Yang YD,et al. Efficacy of combined therapy in patients with hepatitis B virus-related decompensated cirrhosis. World J Gastroenterol,2013,19（22）:3481-3486.